Femasys Initiates Enrollment In Pivotal Trial Of Its Permanent Birth Control Candidate FemBloc
Femasys Initiates Enrollment In Pivotal Trial Of Its Permanent Birth Control Candidate FemBloc
Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting women's unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally invasive, in-office technologies for reproductive health, announced the initiation of enrollment in a prospective multi-center pivotal trial for FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Control (the "FINALE" trial), to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The robust trial is designed to address the high unmet need that exists for women seeking permanent birth control for whom elective surgery remains the only option.
Femasys Inc.（纳斯达克股票代码：FEMY）是一家生物医学公司，致力于通过开发广泛的创新候选产品和产品（包括微创的办公室内生殖健康技术）来满足全球女性未得到满足的需求。该公司宣布开始参加一项前瞻性的多中心关键试验 Fembloc 在Transcervic 的 tratubal OcclusionAL PErmanent Birth Control（“FINALE” 试验），旨在调查其研究性永久节育候选药物FemBloc的安全性和有效性。这项强有力的试验旨在解决寻求永久节育措施的女性存在的高未满足需求，而选择性手术仍然是唯一的选择。